RxDoctor Payments Data

Chesley Murphy, MD

Family Medicine · Mountain Home, ARNPI 1508493610

Payments from drug & device makers

$539in general payments, 2019–2025

Across 19 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$352
  • GSK$61
  • Exact Sciences$43
  • Johnson & Johnson$30
  • Phathom Pharmaceuticals, Inc.$28
  • Mylan Specialty L.p.$26

What the payments were for

  • Food & beverage$539100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$539 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$108,648
Medicare patients
202
Services billed
1,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$58,427
OzempicSemaglutide47$51,480
EliquisApixaban45$39,768
JanuviaSitagliptin Phosphate18$25,224
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$17,521
Combivent RespimatIpratropium/Albuterol Sulfate16$13,049
FarxigaDapagliflozin Propanediol11$11,858
EntrestoSacubitril/Valsartan14$8,968
Spiriva RespimatTiotropium Bromide13$7,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,189
Spiriva HandihalerTiotropium Bromide11$6,946
SymbicortBudesonide/Formoterol Fumarate20$6,246
Breo ElliptaFluticasone/Vilanterol11$4,193
Albuterol Sulfate HfaAlbuterol Sulfate97$2,130
Levothyroxine Sodium137$1,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$352$18,10431 claims
GSKTrelegy Ellipta, Breo Ellipta$61$11,38222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →